Drug Profile
Interferon alpha-2b
Alternative Names: Intron A; SCH 30500; Viraferon; Virtron; YM 14090Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen; Merck & Co
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia; Follicular lymphoma; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Human papillomavirus infections; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 13 Jun 2018 Merk prematurely terminates a phase II/III trial in Melanoma (Adjuvant therapy, Late-stage disease, Metastatic disease) due to sub-optimal accrual (SC, IV) (NCT03552549)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec